Editorial: drug-induced acute pancreatitis: uncommon or commonplace?

Many drugs have been implicated as causing acute pancreatitis (AP), mainly based on the recurrence of pancreatitis following rechallenge with a drug that the patient had been taking at the time of an initial episode of AP. However, estimates of the relative frequency with which drugs cause AP vary widely. This is largely because many patients may be taking a number of drugs, may have co-morbidities such as gallstone disease or hypertriglyceridemia, or may be consuming large amounts of alcohol, making it difficult to determine what actually is the primary cause of an episode of AP. Large, rigorously designed epidemdiological studies are needed to better define the frequency with which the drugs in general cause AP and the specific risk of pancreatitis associated with any individual drug.     

Evidence based guidelines and clinical pathways: complementation or contradiction?

Even methodological sound guidelines will only achieve their goals when the recommendations are transferred into practice. Guideline introduction and dissemination must therefore be accompanied by active implementation measures. For inpatient care clinical pathways can serve as tools, especially taking advantage of their sequential character. Complementary evidence based guidelines can serve as an optimal source of systematically appraised evidence in developing clinical pathways. Considering them is of major help to assure that the content of clinical pathways is in accordance with evidence. The article highlights methodological requirements in guideline and pathway development and gives prospects on how both tools can be used together.     

Editorial: Global elimination of lymphatic filariasis: fact or fantasy?

In 1997, the World Health Assembly resolved to eliminate lymphatic filariasis as a public health problem by the year 2020. By the end of 2004, almost half of the 83 endemic countries had initiated national programmes, providing mass drug administration to an at risk population of approximately 435 million. This remarkable achievement is the result of an enormous amount of technical, financial and political support from public and private sectors at the community, national, regional and global level. As the global programme to eliminate lymphatic filariasis enters its second quarter of operations, there are substantial opportunities to be taken and critical challenges to be addressed. These are the focus of this editorial.     

Practice guidelines do improve patient outcomes: association or causation?

Guidelines have been developed in nephrology and medicine developed to assist practitioners and patients in making decisions about healthcare for specific clinical circumstances. There has been a proliferation of guidelines over the last decade in all areas of medicine, including nephrology. Many of the nephrology guidelines are based on a less robust evidentiary base than guidelines in cardiology or diabetes. There continues to be a debate in medicine as to whether guidelines and their development process actually impact patient outcomes. This article describes the ways in which guidelines may impact patient outcomes in nephrology and emphasizes the role of guidelines in education, research and health policy development such that there is an indirect benefit on medical practice and thus patient outcomes. Our failure to be able to directly attribute any specific guideline to a change in patient outcomes speaks to the complexity of CKD patients, and the difficult in measuring hard outcomes versus process outcomes. Examples of the activities stimulated by guidelines in key areas of nephrology are given. Guidelines are an important component of the application of medical knowledge to medical practice, and need to be contextualized as such. Rigorous evaluation of current implementation techniques and resultant impacts should be undertaken.     

Editorial: fecal granins in IBS: cause or indicator of intestinal or colonic irritation?

Ohman et al. report increased fecal granins in patients with irritable bowel syndrome (IBS). Several interesting questions arise from their observations. Are the granins a cause of the pathophysiology or phenotype in IBS? Is the elevation of granins specific to IBS? What is the cause of increased fecal granin levels? Can fecal granin levels be used to diagnose IBS? Are increased fecal granins an expression of intestinal or colonic irritation? This paper adds to the body of evidence suggesting there are gastrointestinal disturbances in IBS; understanding these disturbances may provide clues to its pathogenesis and optimize management.     

Blood component support in acquired coagulopathic conditions: Is there a method to the madness?

Acquired coagulopathies are often detected by laboratory investigation in clinical practice. There is a poor correlation between mild to moderate abnormalities of laboratory test and bleeding tendency. Patients who are bleeding due to coagulopathy are often managed with various blood components including plasma, platelets, and cryoprecipitate. However, prophylactic transfusion of these products in a nonbleeding patient to correct mild to moderate abnormality of a coagulation test especially preprocedure is not evidence-based. This article reviews the management of bleeding due to oral anticoagulants and antiplatelet agents, disseminated intravascular coagulation, chronic liver disease, and trauma.